As travel destinations reopen, new Covid-19 strains threaten the tourist industry’s revival. RT asked the experts whether the relief from lockdown stress is set to bring about another surge in infections.
The ExeCTU collaborates with healthcare researchers to design and deliver important health-related studies.
The University of Exeter Clinical Trials Unit (ExeCTU) has been instrumental in facilitating three major trials into COVID-19 in the past year.
On this year’s International Clinical Trials Day, we are marking the outstanding contribution the ExeCTU has made in advancing crucial research that builds understanding of improving treatment and care in the face of the pandemic.
The ExeCTU collaborates with healthcare researchers, locally, nationally and internationally, to design and deliver important health-related studies, ensuring clinical research is of the highest quality. Since its inception in 2015, ExeCTU has been actively involved in 30 studies.
E-Mail
IMAGE: Andrew T. Hattersley, DBE, FMedSci, FRS
2021 Harold Hamm International Prize for Biomedical Research in Diabetes award winner view more
Credit: University of Exeter Medical School, U.K. OKLAHOMA CITY - Andrew T. Hattersley, DBE, FMedSci, FRS, has been named the recipient of the 2021 Harold Hamm International Prize for Biomedical Research in Diabetes. Hattersley, Professor of Molecular Medicine, University of Exeter Medical School, U.K., was nominated by Alvin Powers, M.D., Vanderbilt University; and Juleen Zierath, Ph.D., Karolinska Institute, Sweden, and University of Copenhagen, Denmark. The Hamm Prize recognizes and encourages lasting advances in the field of diabetes research. It is awarded to an individual who has either demonstrated lifelong contributions to the field or realized a singular advance, especially one that promotes curative potential. The honor includes a $250,000 award - the largest of its kind in the world - and will be award